Federation Des Caisses Desjardins Du Quebec Crispr Therapeutics Ag Transaction History

Federation Des Caisses Desjardins Du Quebec

$23.7 Billion
Q3 2025

A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 2,254 shares of CRSP stock, worth $124,691. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,254

Previous 2,072 8.78%

Holding current value

$124,691

Previous $100,000 46.0%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$48.51 - $68.14 $8,828 - $12,401	182 Added 8.78%	2,254 $146,000
Q2 2025 Aug 14, 2025	BUY	$31.27 - $48.64 $7,817 - $12,160	250 Added 13.72%	2,072 $100,000
Q1 2025 May 15, 2025	SELL	$34.03 - $53.02 $1,395 - $2,173	-41 Reduced 2.2%	1,822 $62,000
Q4 2024 Feb 13, 2025	BUY	$38.65 - $55.15 $34,089 - $48,642	882 Added 89.91%	1,863 $73,000
Q3 2024 Nov 13, 2024	SELL	$44.62 - $62.75 $2,543 - $3,576	-57 Reduced 5.49%	981 $46,000

Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $358 - $477	7 Added 0.68%	1,038 $56,000
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $62,550 - $91,882	1,031 New	1,031 $70.3 Million
Q4 2023 Aug 14, 2024	SELL	$38.62 - $72.18 $3,900 - $7,290	-101 Reduced 11.21%	800 $50.1 Million
Q2 2023 Aug 14, 2024	SELL	$43.47 - $67.77 $1,825 - $2,846	-42 Reduced 4.45%	901 $50.6 Million
Q1 2023 Aug 14, 2024	BUY	$41.0 - $56.12 $17,425 - $23,851	425 Added 82.05%	943 $42.7 Million
Q4 2022 Aug 14, 2024	SELL	$39.19 - $65.67 $12,736 - $21,342	-325 Reduced 38.55%	518 $21.1 Million
Q3 2022 Aug 14, 2024	BUY	$61.1 - $83.78 $6,110 - $8,378	100 Added 13.46%	843 $55.1 Million
Q2 2022 Aug 14, 2024	SELL	$43.23 - $73.83 $3,674 - $6,275	-85 Reduced 10.27%	743 $45.2 Million
Q1 2022 Aug 14, 2024	SELL	$53.19 - $79.24 $11,169 - $16,640	-210 Reduced 20.23%	828 $52 Million
Q4 2021 Aug 30, 2024	SELL	$70.09 - $111.29 $3,854 - $6,120	-55 Reduced 5.3%	983 $74.5 Million
Q3 2021 Aug 30, 2024	SELL	$110.2 - $156.64 $24,244 - $34,460	-220 Reduced 17.49%	1,038 $116 Million
Q2 2021 Aug 30, 2024	BUY	$100.84 - $161.89 $22,184 - $35,615	220 Added 21.19%	1,258 $204 Million
Q1 2021 Aug 30, 2024	BUY	$110.72 - $210.04 $19,818 - $37,597	179 Added 16.13%	1,289 $157 Million
Q4 2020 Aug 30, 2024	BUY	$79.67 - $173.23 $8,524 - $18,535	107 Added 10.67%	1,110 $170 Million
Q3 2020 Aug 30, 2024	SELL	$78.5 - $100.64 $258,893 - $331,910	-3,298 Reduced 76.68%	1,003 $83.9 Million
Q2 2020 Aug 30, 2024	SELL	$38.5 - $76.05 $798,374 - $1.58 Million	-20,737 Reduced 82.82%	4,301 $317 Million
Q1 2020 Aug 30, 2024	BUY	$33.68 - $62.53 $793,433 - $1.47 Million	23,558 Added 1591.76%	25,038 $1.07 Billion
Q4 2019 Aug 30, 2024	SELL	$36.68 - $73.13 $3,301 - $6,581	-90 Reduced 5.73%	1,480 $90.1 Million
Q2 2019 Aug 30, 2024	SELL	$35.45 - $48.2 $1,063 - $1,446	-30 Reduced 1.88%	1,570 $73.9 Million
Q1 2019 Aug 30, 2024	SELL	$28.02 - $40.87 $2,802 - $4,086	-100 Reduced 5.88%	1,600 $57.2 Million
Q4 2018 Aug 30, 2024	BUY	$22.73 - $42.34 $15,047 - $28,029	662 Added 63.78%	1,700 $48.6 Million
Q3 2018 Aug 30, 2024	SELL	$44.35 - $65.71 $13,305 - $19,712	-300 Reduced 6.48%	4,330 $192 Million
Q2 2018 Aug 30, 2024	BUY	$42.62 - $73.59 $150,448 - $259,772	3,530 Added 320.91%	4,630 $272 Million
Q1 2018 Aug 30, 2024	BUY	$23.52 - $58.17 $19,992 - $49,444	850 Added 340.0%	1,100 $50.3 Million
Q3 2017 Aug 30, 2024	SELL	$16.75 - $20.66 $9,212 - $11,363	-550 Reduced 68.75%	250 $4.47 Million
Q2 2017 Aug 30, 2024	BUY	N/A	152 Added 23.46%	800 $12.8 Million
Q1 2017 Aug 30, 2024	SELL	N/A	-390	648 $14.1 Million

Others Institutions Holding CRSP

# of Institutions

547

Shares Held

67.7M

Call Options Held

3.5M

Put Options Held

3.08M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.32B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account

Federation Des Caisses Desjardins Du Quebec Crispr Therapeutics Ag Transaction History